Hepatitis D Market Analysis Highlights Growth To $0.92 Billion By 2030 At 4.1% CAGR

The hepatitis D market is positioned for steady growth as advancements in treatment and prevention continue to develop. Increasing awareness, improved diagnostic methods, and ongoing research into novel therapies are expected to fuel the expansion of this specialized medical sector. Let's explore the current market size, leading companies, key trends, and segmentation within the hepatitis D landscape.

Anticipated Growth and Market Size of the Hepatitis D Market
The hepatitis D market is set to expand steadily and reach a valuation of $0.93 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.1%. This progress is driven by intensified research efforts aimed at discovering new HDV treatments, a growing emphasis on combination antiviral therapies, and the broadening implementation of vaccination programs designed to prevent infection. Additionally, heightened awareness among high-risk groups and increased investments into rare liver disease research are contributing significantly to market growth. Key trends shaping the market include prioritizing early detection of co-infections, wider adoption of advanced serologic testing, growing demand for specialized treatment protocols, expansion of disease management in hospital settings, and greater focus on increasing disease awareness.

The hepatitis d market size has grown steadily in recent years. It will grow from $0.76 billion in 2025 to $0.79 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to improved hepatitis B screening coverage, increased recognition of HDV severity, expansion of diagnostic capabilities, rising referral to specialty centers, availability of targeted therapies.

Download a free sample of the hepatitis d market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21202&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Players Influencing the Hepatitis D Market
Several prominent companies are actively shaping the hepatitis D market landscape. These include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc., VBI Vaccines Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A., Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc., Bluejay Therapeutics Inc., Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc., and Biorex Diagnostics Ltd.

A notable collaboration took place in October 2023 when Gilead Sciences Inc., a US-based biopharmaceutical firm, joined forces with Assembly Biosciences Inc. to push forward the development of next-generation antiviral treatments. This partnership focuses on creating innovative therapies targeting serious viral infections, including hepatitis B, herpesviruses, and hepatitis D. Assembly Biosciences is recognized for its development of small-molecule therapeutics aimed at combating serious viral diseases, especially hepatitis B virus (HBV) and herpes viruses.

View the full hepatitis d market report:
https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends and Opportunities in the Hepatitis D Market
The hepatitis D sector is witnessing a shift toward innovative therapies such as RNA-targeted antiviral treatments, which hold promise for improving patient outcomes by directly interfering with viral RNA replication. This approach can effectively reduce viral loads and limit infection progression by disrupting viral protein production or silencing viral genes. For example, in December 2024, Vir Biotechnology Inc., a US biotechnology company, earned both the U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and the European Medicines Agency (EMA) Priority Medicines (PRIME) designation for its combination therapy involving tobevibart and elebsiran. This treatment is designed to address chronic hepatitis delta (CHD), signaling significant progress in therapeutic innovation.

More companies are also investing in broadening treatment options and enhancing disease management protocols. These efforts are anticipated to meet the unmet needs of patients with chronic hepatitis D infection, providing more effective and targeted care.

Breakdown of Hepatitis D Market Segments and Key Areas
This report segments the hepatitis D market across several dimensions:
1) By Type: Acute and Chronic
2) By Diagnosis Method: Blood Tests, Elastography, Liver Biopsy, Serologic Testing, and Other Diagnostic Techniques
3) By Distribution Channel: Hospital Pharmacies and Retail Pharmacies
4) By End Users: Clinics, Hospitals, and Other Healthcare Facilities

Further classification includes subtypes such as:
- Acute: Self-limiting Acute Hepatitis D and Severe Acute Hepatitis D
- Chronic: Compensated Chronic Hepatitis D and Decompensated Chronic Hepatitis D

These categorizations help in understanding the market dynamics and identifying areas that hold the largest shares or exhibit the strongest growth potential.

What's included in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.